CTLA4 and B-cell non-Hodgkin lymphoma: mAbs targeting CTLA-4 or PD-1 have demonstrated notable clinical efficacy in patients with HMs, particularly in those with Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma.